Верткин А., Тополянский А.В. Лечение артериальной гипертензии: комбинация лекарственных средств и комбинированные препараты. РМЖ, 2010; 18(10):708-710.

Верткин АЛ., Лоран О.Б., Тополянский А.В. и др. Клиническая эффективность и влияние р-адреноблокаторов на копулятивную функцию у больных с артериальной гипертензией. Кардиология, 2002; 42(9):39-42.

Дедов И.И., Калинченко С.Ю. Возрастной андрогенный дефицит у мужчин. Практическая медицина, 2006; 236.

Исаева Е.Н. Распространенность метаболического синдрома в неорганизованной популяции с учетом разных критериев его диагностики. Казанский медицинский журнал, 2012.

Калинченко С.Ю., Лепетухин А.Е., Кварацхелия М.В., Гончаров Н.П., Шестакова М.В. Влияние заместительной гормональной терапии андрогенами на эритропоэз. Материалы IVВсероссийского Конресса «Мужское Здоровье», 12-14 ноября, Москва, 2008. D 10, стр. 35.

Консенсус российских экспертов по проблеме метаболического синдрома в Российской Федерации: определение, диагностические критерии, первичная профилактика и лечение. Профилактическая медицина, 2010; 5:27-32. '

Мазо Е.Б. и др. Влияние длительного приема варденафила на эректильную и эндотелиальную функцию у больных с артериогенной эректильной дисфункцией.

Недогода С.В., Саласюк А.С., Барыкина И.Н., Ледяева А.А., Цома В.В., Чумачек Е.В. Сравнительный анализ эффективности применения селективного b-адреноблокатора небиволола и блокатора рецепторов ангиотензина II валсартана у мужчин с артериальной гипертонией, метаболическим синдромом и эректильной дисфункцией. Кардиосоматика, 2013; 2:57-76.

Оганов Р.Г., Масленникова Г.Я. Гендерные различия кардиоваскулярной патологии. Кардиоваскулярная терапия и профилактика, 2012; 11(4):101-104.

Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). 2010.

Ротарь О.П. и др. Распространенность метаболического синдрома в разных городах РФ. Российский кардиологический журнал, 2012; 2.

Тишова Ю.А., Мсхалая Г.Ж., Калинченко С.Ю. Возрастной гипогонадизм у мужчин с метаболическим синдромом. Сахарный диабет, 2010.

Шальнова С.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал, 2012; 5 (97):6-11.

AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8(6):439-456.

Alhathal N., Elshal A.M., Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Canadian Urological Association Journal, 2012; 6(4):269.

Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes, 2010; 17:224–232

Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf), 2000;53:517-22.

Bajos N, Wellings K, Laborde C, Moreau C; CSF Group. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ, 2010; 340:c2573

Bal K, Oder M, Sahin AS, et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology, 2007;69:356-.360

Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2010; 95(6):2536-2559.

Böhm M. et al. Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation, 2010; 121 (12):1439-1446.

Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol, 2011; 40:189-207.

Braun M. et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. International journal of impotence research, 2000; 12 (6):305-311.

Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med, 2010; 7(4 Pt 2):1627-1656.

Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1[%] hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med, 2011; 8:284-93.

Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care, 2009; 32:1049–1051.

Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 24 October 2010.

Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology, 2004; 55 (6):3145–52.

Davis BJ, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 2006; 55(2):496-505.

Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure, 2003; 12 (S2):29-34.

Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens Greenwich, 2002; 4 (6):424-32.

Fogari R. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. European journal of clinical pharmacology, 2002; 58 (3):177-180.

Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Cur Urol Rep, 2003; 4:457–65.

Gazzaruso C. et al. Erectile Dysfunction as a Predictor of Cardiovascular Events and Death in Diabetic Patients With Angiographically Proven Asymptomatic Coronary Artery DiseaseA Potential Protective Role for Statins and 5-Phosphodiesterase Inhibitors. Journal of the American College of Cardiology, 2008; 51 (21):2040-2044.

Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol, 2006; 50:940-7.

Guzik TJ, Mangalat D, Korbut R. Adipocytokines: novel link between inflammation and vascular function? J Physiol Pharmacol, 2006; 57:505-528.

Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf), 2005; 63:381-94.

Jansson PAE, et al. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes care, 1996; 19 (2):160-164.

Kim YW, Park SY, Kim JY, Huh JY. Metformin Restores the Penile Expression of Nitric Oxide Synthase in High Fat–Fed Obese Rats. J Androl, 2007; 26 (3):34–8.

Kupelian V, Shabsigh R, Araujo AB, O’Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol, 2006; 176:222–226.

Laaksonen DE, Lakka HM, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol, 2002; 156:1070-1077.

Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 2004; 27:1036-1041.

Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab, 2005; 90:712-719.

Larsen SH, Wagner G, Heitmann BL. Sexual function and obesity. Int J Obes (Lond), 2007; 31:1189-1198.

Liao CH, et al. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism. Andrology, 2013.

MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update, 2010; 16:293-311.

Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med, 2009; 6:1232-1247.

Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA, 2006; 296(19):2351-2361.

Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology, 2001; 37 (5):1344-1350.

Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, et al. (2004). Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology, 145 (5):2253-2263.

Piro S, et al. Effects of metformin on oxidative stress, adenine nucleotides balance, and glucose-induced insulin release impaired by chronic free fatty acids exposure in rat pancreatic islets. Journal of endocrinological investigation, 2012; 35 (5):504.

Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl, 2006; 27:165-175.

Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol, 2011; 165(5):675-685.

Saenz de Tejada I, Angulo J, Cellek S, et al. Physiology of erectile function. J Sex Med, 2004; 1:254-

Scarpello JHB. Improving survival with metformin: the evidence base today. Diabetes Metab, 2003; 29: 6S36-43.

Schwarz Ernst R, ed. Erectile Dysfunction. Oxford University Press, 2013.

Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res, 2009; Jan-Feb;21(1):9-23.

Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol. 2003; 5(suppl 1):S34-S40.

Stellato RK, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes care, 2000; 23 (4):490-494.

Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J, 2009; 276:5755-5767.

Traish AM, Munarriz R, O’Connell L, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl, 2003; 24:381-7.

Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med, 2010; 363:123-135.

Yassin AA, Saad F, Gooren IJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia, 2008; 40:259-264.

Zhang XH, Morelli A, Luconi M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol, 2005; 47:409-16; discussion 416.